1. Pink Sheet
  2. >>Agency Leadership

New Years' Resolutions

 
• By Kate Rawson

If a panel of analysts are correct, the coming year will bring the reintroduction of Biogen-Idec's Tysabri, approval of Merck's human papilloma virus vaccine Gardasil and a continued stalemate over generic biologics. We asked top pharmaceutical analysts to weigh in on the events they think will move the market in 2006.

By Kate Rawson

The coming year will bring Food & Drug Administration approval of a first-ever cancer vaccine, the reintroduction of a withdrawn multiple sclerosis therapy and a continued stalemate in the ongoing...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Agency Leadership

More from Pink Sheet